Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Eucrisa for Atopic Dermatitis: Measuring and Improving Adherence to Topical Eucrisa in Patients With Atopic Dermatitis
Brief Summary: Patients with mild to moderate atopic dermatitis will be asked to participate in helping the study team determine how well the medication works for atopic dermatitis. Participants will not be told that adherence will be monitored. Patients will be dispensed topical crisaborole 2% ointment (Eucrisa®) in a medication tube fitted with a Medication Event Monitoring System (MEMS) cap if they agree to participate. This cap records dates and times the bottle is opened and this data can be downloaded and tabulated with the associated software.

Investigators and subjects will be blinded to the adherence data until the final treatment (12 month) session. The study subjects will be randomized to two groups. After baseline visit, both groups will come for a follow-up visit at 1 month, 3 months, 6 months, and 12 months. The intervention group will also be asked to complete an online treatment response survey designed to improve adherence at weekly intervals for 6 weeks, then monthly thereafter.

The study will consist of a 12-month Treatment Phase. Study subjects will be instructed to apply the medication twice daily (morning and evening) to all of their AD lesions. They will be instructed to apply the smallest amount of study medication possible that is sufficient to cover all lesions. These instructions are standard-of-care for patients with AD.

Subjects will be asked to bring their medication tubes with them at each visit. At each visit, the study coordinator will weigh the medication tube and download the MEMS cap data. Disclosure of the adherence monitoring will occur at the 12 month visit (or end of treatment), at which time the results of the subject's adherence behavior will be used to supply individualized treatment options for each subject (feedback session).

At each visit, drug tubes will be measured for weight to determine the amount of study medication used. This data will be correlated with the extent of BSA involved and the response of the disease. The MEMS caps will be downloaded at each visit.


Options:
A: Arm Label: Arm 1 - Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: EUCRISA | Arm Label: Arm 2 - Online Treatment Response; Type: EXPERIMENTAL; Interventions: Behavioral: Online Treatment response, Drug: EUCRISA | Intervention Type: BEHAVIORAL; Name: Online Treatment response; Assigned to Arm(s): Arm 2 - Online Treatment Response | Intervention Type: DRUG; Name: EUCRISA; Assigned to Arm(s): Arm 1 - Standard of Care, Arm 2 - Online Treatment Response
B: Arm Label: Crisaborole ointment; Type: EXPERIMENTAL; Interventions: Drug: Crisaborole Ointment | Arm Label: Crisaborole Placebo Vehicle; Type: PLACEBO_COMPARATOR; Interventions: Drug: Crisaborole Placebo Vehicle | Intervention Type: DRUG; Name: Crisaborole Ointment; Assigned to Arm(s): Crisaborole ointment | Intervention Type: DRUG; Name: Crisaborole Placebo Vehicle; Assigned to Arm(s): Crisaborole Placebo Vehicle
C: Arm Label: Vehicle Control (VC) Period: Vehicle Cream BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle cream | Arm Label: VC Period: Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: VC Period: Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: LTS Period: Ruxolitinib 0.75% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Arm Label: LTS Period: Ruxolitinib 1.5% Cream BID; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib cream | Intervention Type: DRUG; Name: Ruxolitinib cream; Assigned to Arm(s): LTS Period: Ruxolitinib 0.75% Cream BID, LTS Period: Ruxolitinib 1.5% Cream BID, LTS Period: Vehicle Cream to Ruxolitinib 1.5% Cream BID, Long-Term Safety (LTS) Period: Vehicle Cream to Ruxolitinib 0.75% Cream BID, VC Period: Ruxolitinib 0.75% Cream BID, VC Period: Ruxolitinib 1.5% Cream BID | Intervention Type: DRUG; Name: Vehicle cream; Assigned to Arm(s): Vehicle Control (VC) Period: Vehicle Cream BID
D: Arm Label: Treatment group A; Type: EXPERIMENTAL; Interventions: Drug: Tofacitinib ointment 20mg/g | Arm Label: Treatment B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo ointment (Vehicle) | Intervention Type: DRUG; Name: Tofacitinib ointment 20mg/g; Assigned to Arm(s): Treatment group A | Intervention Type: DRUG; Name: Placebo ointment (Vehicle); Assigned to Arm(s): Treatment B

Answer: A